Bionetix, Inc.

[Not Yet Scheduled]
Bionetix, Inc. (“Bionetix”) is a development stage biotech focusing on the development of innovative small molecule based new drugs. With the aim of providing novel solutions to patients with high unmet medical needs, Bionetix was founded in 2017 and is developing 2 phase I stage candidates (NTX-301 oral targeted anti-cancer agent and NTX-101, topical glaucoma treatment) along with other early stage programs in oncology area. NTX-301 is an orally available Best-in-class DNMT1 inhibitor targeting MDS and AML. NTX-301’s unique property, high potency/excellent safety profile/ease of administration, makes NTX-301 as an attractive candidate. Bionetix has received approval for phase I clinical of NTX-301 from US FDA in February 2020 and aims to initiate the phase I study in the first half of 2020.
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
NTX-301, Best-in-class DNMT1 inhibitor for MDS/AML
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
CEO/Founder
Bionetix, Inc.